Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1998 Aug;78(3):282–288. doi: 10.1038/bjc.1998.486

Immunotherapy in lung cancer.

M Al-Moundhri, M O'Brien, B E Souberbielle
PMCID: PMC2063029  PMID: 9703271

Abstract

More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology. In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct therapeutic action on all subtypes of lung cancer.

Full text

PDF
282

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthony H. M., Mearns A. J., Mason M. K., Scott D. G., Moghissi K., Deverall P. B., Rozycki Z. J., Watson D. A. Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax. 1979 Feb;34(1):4–12. doi: 10.1136/thx.34.1.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ardizzoni A., Addamo G. F., Baldini E., Borghini U., Portalone L., De Marinis F., Lionetto R., Conte P. F., Bruzzi P., Pennucci M. C. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. Br J Cancer. 1995 Jan;71(1):115–119. doi: 10.1038/bjc.1995.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ardizzoni A., Bonavia M., Viale M., Baldini E., Mereu C., Verna A., Ferrini S., Cinquegrana A., Molinari S., Mariani G. L. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer. 1994 Mar 1;73(5):1353–1360. doi: 10.1002/1097-0142(19940301)73:5<1353::aid-cncr2820730508>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Ardizzoni A., Salvati F., Rosso R., Bruzzi P., Rubagotti A., Pennucci M. C., Mariani G. L., De Marinis F., Pallotta G., Antilli A. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force. Cancer. 1993 Nov 15;72(10):2929–2935. doi: 10.1002/1097-0142(19931115)72:10<2929::aid-cncr2820721012>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  5. Boon T., Coulie P. G., Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997 Jun;18(6):267–268. doi: 10.1016/s0167-5699(97)80020-5. [DOI] [PubMed] [Google Scholar]
  6. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan-Feb;43(1):7–26. doi: 10.3322/canjclin.43.1.7. [DOI] [PubMed] [Google Scholar]
  7. Bowman A., Fergusson R. J., Allan S. G., Stewart M. E., Gregor A., Cornbleet M. A., Greening A. P., Crompton G. K., Leonard R. C., Smyth J. F. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol. 1990 Sep;1(5):351–353. doi: 10.1093/oxfordjournals.annonc.a057773. [DOI] [PubMed] [Google Scholar]
  8. Ciriaco P., Rendina E. A., Venuta F., De Giacomo T., Della Rocca G., Flaishman I., Baroni C., Cortesi E., Bonsignore G., Ricci C. Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results. Eur J Cardiothorac Surg. 1995;9(6):305–309. doi: 10.1016/s1010-7940(05)80187-3. [DOI] [PubMed] [Google Scholar]
  9. Davis S., Mietlowski W., Rohwedder J. J., Griffin J. P., Neshat A. A. Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study. Cancer. 1982 Aug 15;50(4):646–651. doi: 10.1002/1097-0142(19820815)50:4<646::aid-cncr2820500405>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  10. Doyle A., Martin W. J., Funa K., Gazdar A., Carney D., Martin S. E., Linnoila I., Cuttitta F., Mulshine J., Bunn P. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985 May 1;161(5):1135–1151. doi: 10.1084/jem.161.5.1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Edwards F. R. Use of BCG as an immunostimulant after resection of carcinoma of the lung: a two-year assessment of a trial of 500 patients. Thorax. 1979 Dec;34(6):801–806. doi: 10.1136/thx.34.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Elshami A. A., Kucharczuk J. C., Zhang H. B., Smythe W. R., Hwang H. C., Litzky L. A., Kaiser L. R., Albelda S. M. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996 Jan 20;7(2):141–148. doi: 10.1089/hum.1996.7.2-141. [DOI] [PubMed] [Google Scholar]
  13. Faradji A., Bohbot A., Schmitt-Goguel M., Roeslin N., Dumont S., Wiesel M. L., Lallot C., Eber M., Bartholeyns J., Poindron P. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother. 1991;33(5):319–326. doi: 10.1007/BF01756597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fischer J. R., Darjes H., Lahm H., Schindel M., Drings P., Krammer P. H. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer. 1994;30A(14):2125–2129. doi: 10.1016/0959-8049(94)00364-b. [DOI] [PubMed] [Google Scholar]
  15. Gaken J. A., Hollingsworth S. J., Hirst W. J., Buggins A. G., Galea-Lauri J., Peakman M., Kuiper M., Patel P., Towner P., Patel P. M. Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Hum Gene Ther. 1997 Mar 1;8(4):477–488. doi: 10.1089/hum.1997.8.4-477. [DOI] [PubMed] [Google Scholar]
  16. Garaci E., Lopez M., Bonsignore G., Della Giulia M., D'Aprile M., Favalli C., Rasi G., Santini S., Capomolla E., Vici P. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. 1995 Dec;31A(13-14):2403–2405. doi: 10.1016/0959-8049(95)00477-7. [DOI] [PubMed] [Google Scholar]
  17. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  18. Herskovic A., Bauer M., Seydel H. G., Yesner R., Doggett R. L., Perez C. A., Durbin L. M., Zinninger M. Post-operative thoracic irradiation with or without levamisole in non-small cell lung cancer: results of a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):37–42. doi: 10.1016/0360-3016(88)90048-x. [DOI] [PubMed] [Google Scholar]
  19. Hoffmann T. H., Ransdell H. T. Comparison of lobectomy and wedge resection for carcinoma of the lung. J Thorac Cardiovasc Surg. 1980 Feb;79(2):211–217. [PubMed] [Google Scholar]
  20. Hollinshead A., Stewart T. H., Takita H., Dalbow M., Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer. 1987 Sep 15;60(6):1249–1262. doi: 10.1002/1097-0142(19870915)60:6<1249::aid-cncr2820600616>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  21. Holmes E. C., Hill L. D., Gail M. A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group. Ann Surg. 1985 Sep;202(3):335–341. doi: 10.1097/00000658-198509000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Huang M., Wang J., Lee P., Sharma S., Mao J. T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S. M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 1995 Sep 1;55(17):3847–3853. [PubMed] [Google Scholar]
  23. Jansen H. M., The T. H., de Gast G. C., Esselink M. T., van der Wal A. M., Orie N. G. Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax. 1978 Aug;33(4):429–438. doi: 10.1136/thx.33.4.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jansen R. L., Slingerland R., Goey S. H., Franks C. R., Bolhuis R. L., Stoter G. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) 1992 Jul;12(1):70–73. doi: 10.1097/00002371-199207000-00009. [DOI] [PubMed] [Google Scholar]
  25. Jett J. R., Maksymiuk A. W., Su J. Q., Mailliard J. A., Krook J. E., Tschetter L. K., Kardinal C. G., Twito D. I., Levitt R., Gerstner J. B. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov;12(11):2321–2326. doi: 10.1200/JCO.1994.12.11.2321. [DOI] [PubMed] [Google Scholar]
  26. Kataja V., Yap A. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study. Eur J Cancer. 1995;31A(1):35–40. [PubMed] [Google Scholar]
  27. Kelly K., Crowley J. J., Bunn P. A., Jr, Hazuka M. B., Beasley K., Upchurch C., Weiss G. R., Hicks W. J., Gandara D. R., Rivkin S. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec;13(12):2924–2930. doi: 10.1200/JCO.1995.13.12.2924. [DOI] [PubMed] [Google Scholar]
  28. Kimura H., Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer. 1996 Jun;14(2-3):301–314. doi: 10.1016/0169-5002(96)00555-7. [DOI] [PubMed] [Google Scholar]
  29. Kimura H., Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer. 1995 Aug;13(1):31–44. doi: 10.1016/0169-5002(95)00478-j. [DOI] [PubMed] [Google Scholar]
  30. Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A. L., Gatter K. C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996 Jan;73(2):148–153. doi: 10.1038/bjc.1996.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kradin R. L., Kurnick J. T., Lazarus D. S., Preffer F. I., Dubinett S. M., Pinto C. E., Gifford J., Davidson E., Grove B., Callahan R. J. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989 Mar 18;1(8638):577–580. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  32. Lissoni P., Barni S., Rovelli F., Brivio F., Ardizzoia A., Tancini G., Conti A., Maestroni G. J. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer. 1993;29A(2):185–189. doi: 10.1016/0959-8049(93)90170-k. [DOI] [PubMed] [Google Scholar]
  33. Mandanas R., Einhorn L. H., Wheeler B., Ansari R., Lutz T., Miller M. E. Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer. A Hoosier Oncology Group phase II trial. Am J Clin Oncol. 1993 Dec;16(6):519–521. doi: 10.1097/00000421-199312000-00012. [DOI] [PubMed] [Google Scholar]
  34. Mattson K., Niiranen A., Pyrhönen S., Holsti L. R., Holsti P., Kumpulainen E., Cantell K. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer. 1992;28A(8-9):1387–1391. doi: 10.1016/0959-8049(92)90526-8. [DOI] [PubMed] [Google Scholar]
  35. Maurer L. H., Pajak T., Eaton W., Comis R., Chahinian P., Faulkner C., Silberfarb P. M., Henderson E., Rege V. B., Baldwin P. E. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol. 1985 Jul;3(7):969–976. doi: 10.1200/JCO.1985.3.7.969. [DOI] [PubMed] [Google Scholar]
  36. McKneally M. F., Maver C., Lininger L., Kausel H. W., McIlduff J. B., Older T. M., Foster E. D., Alley R. D. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg. 1981 Apr;81(4):485–492. [PubMed] [Google Scholar]
  37. Miller A. B., Taylor H. E., Baker M. A., Dodds D. J., Falk R., Frappier A., Hill D. P., Jindani A., Landi S., Macdonald A. S. Oral administration of BCG as an adjuvant to surgical treatment of carcinoma of the bronchus. Can Med Assoc J. 1979 Jul 7;121(1):45–54. [PMC free article] [PubMed] [Google Scholar]
  38. Pardoll D. M. Cancer vaccines. Immunol Today. 1993 Jun;14(6):310–316. doi: 10.1016/0167-5699(93)90051-L. [DOI] [PubMed] [Google Scholar]
  39. Perez C. A., Bauer M., Emami B. N., Byhardt R., Brady L. W., Doggett R. L., Gardner P., Zinninger M. Thoracic irradiation with or without levamisole (NSC #177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG. Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1337–1346. doi: 10.1016/0360-3016(88)90229-5. [DOI] [PubMed] [Google Scholar]
  40. Perlin E., Oldham R. K., Weese J. L., Heim W., Reid J., Mills M., Miller C., Blom J., Green D., Bellinger S., Jr Carcinoma of the lung: immunotherapy with intradermal BCG and allogeneic tumor cells. Int J Radiat Oncol Biol Phys. 1980 Aug;6(8):1033–1039. doi: 10.1016/0360-3016(80)90113-3. [DOI] [PubMed] [Google Scholar]
  41. Pines A. BCG plus levamisole following irradiation of advanced squamous bronchial carcinoma. Int J Radiat Oncol Biol Phys. 1980 Aug;6(8):1041–1042. doi: 10.1016/0360-3016(80)90114-5. [DOI] [PubMed] [Google Scholar]
  42. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997 Jun;18(6):263–266. doi: 10.1016/s0167-5699(97)80019-9. [DOI] [PubMed] [Google Scholar]
  43. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J. L., Li S., Roig J., Olazábal A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153–158. doi: 10.1056/NEJM199401203300301. [DOI] [PubMed] [Google Scholar]
  44. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  46. Roth J. A., Nguyen D., Lawrence D. D., Kemp B. L., Carrasco C. H., Ferson D. Z., Hong W. K., Komaki R., Lee J. J., Nesbitt J. C. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996 Sep;2(9):985–991. doi: 10.1038/nm0996-985. [DOI] [PubMed] [Google Scholar]
  47. Salvati F., Rasi G., Portalone L., Antilli A., Garaci E. Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Res. 1996 Mar-Apr;16(2):1001–1004. [PubMed] [Google Scholar]
  48. Sause W. T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., Emami B., Curran W. J., Byhardt R. W., Turrisi A. T. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995 Feb 1;87(3):198–205. doi: 10.1093/jnci/87.3.198. [DOI] [PubMed] [Google Scholar]
  49. Schwartz R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992 Dec 24;71(7):1065–1068. doi: 10.1016/s0092-8674(05)80055-8. [DOI] [PubMed] [Google Scholar]
  50. Scudeletti M., Filaci G., Imro M. A., Motta G., Di Gaetano M., Pierri I., Tongiani S., Indiveri F., Puppo F. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. Cancer Immunol Immunother. 1993 Jul;37(2):119–124. doi: 10.1007/BF01517044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Silva R. R., Bascioni R., Rossini S., Zuccatosta L., Mattioli R., Pilone A., Delprete S., Battelli N., Gasparini S., Battelli T. A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer. Tumori. 1996 Jan-Feb;82(1):68–71. doi: 10.1177/030089169608200115. [DOI] [PubMed] [Google Scholar]
  52. Souter R. G., Gill P. G., Gunning A. J., Morris P. J. Failure of specific active immunotherapy in lung cancer. Br J Cancer. 1981 Oct;44(4):496–501. doi: 10.1038/bjc.1981.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Stack B. H., McSwan N., Stirling J. M., Hole D. J., Spilg W. G., McHattie I., Elliott J. A., Gillis C. R., Turner M. A., White R. G. Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer. Thorax. 1982 Aug;37(8):588–593. doi: 10.1136/thx.37.8.588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Stewart T. H., Hollinshead A. C., Harris J. E., Belanger R., Crepeau A., Hooper G. D., Sachs H. J., Klaassen D. J., Hirte W., Rapp E. Immunochemotherapy of lung cancer. Ann N Y Acad Sci. 1976;277(00):436–466. doi: 10.1111/j.1749-6632.1976.tb41720.x. [DOI] [PubMed] [Google Scholar]
  55. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg. 1981 Nov;82(5):649–657. [PubMed] [Google Scholar]
  56. Takita H., Hollinshead A. C., Adler R. H., Bhayana J., Ramundo M., Moskowitz R., Rao U. N., Raman S. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis. J Surg Oncol. 1991 Jan;46(1):9–14. doi: 10.1002/jso.2930460104. [DOI] [PubMed] [Google Scholar]
  57. Tan Y., Xu M., Wang W., Zhang F., Li D., Xu X., Gu J., Hoffman R. M. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res. 1996 Jul-Aug;16(4A):1993–1998. [PubMed] [Google Scholar]
  58. Treat J., Kaiser L. R., Sterman D. H., Litzky L., Davis A., Wilson J. M., Albelda S. M. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Hum Gene Ther. 1996 Oct 20;7(16):2047–2057. doi: 10.1089/hum.1996.7.16-2047. [DOI] [PubMed] [Google Scholar]
  59. Tummarello D., Graziano F., Mari D., Cetto G., Pasini F., Antonio S., Isidori P., Gasparini S. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy. Anticancer Res. 1994 Sep-Oct;14(5B):2221–2227. [PubMed] [Google Scholar]
  60. Tursz T., Cesne A. L., Baldeyrou P., Gautier E., Opolon P., Schatz C., Pavirani A., Courtney M., Lamy D., Ragot T. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst. 1996 Dec 18;88(24):1857–1863. doi: 10.1093/jnci/88.24.1857. [DOI] [PubMed] [Google Scholar]
  61. Wakimoto H., Abe J., Tsunoda R., Aoyagi M., Hirakawa K., Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 1996 Apr 15;56(8):1828–1833. [PubMed] [Google Scholar]
  62. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  63. Weynants P., Lethé B., Brasseur F., Marchand M., Boon T. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer. 1994 Mar 15;56(6):826–829. doi: 10.1002/ijc.2910560612. [DOI] [PubMed] [Google Scholar]
  64. Weynants P., Marchandise F. X., Sibille Y. Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Eur Respir J. 1997 Aug;10(8):1703–1719. doi: 10.1183/09031936.97.10081703. [DOI] [PubMed] [Google Scholar]
  65. Wright P. W., Hill L. D., Peterson A. V., Jr, Pinkham R., Johnson L., Ivey T., Bernstein I., Bagley C., Anderson R. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer. Cancer Treat Rep. 1978 Nov;62(11):1671–1675. [PubMed] [Google Scholar]
  66. Yang S. C., Owen-Schaub L., Mendiguren-Rodriguez A., Grimm E. A., Hong W. K., Roth J. A. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha. J Thorac Cardiovasc Surg. 1990 Jan;99(1):8–13. [PubMed] [Google Scholar]
  67. Yemini M., Borenstein R., Dreazen E., Apelman Z., Mogilner B. M., Kessler I., Lancet M. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985 Mar 1;151(5):574–577. doi: 10.1016/0002-9378(85)90141-3. [DOI] [PubMed] [Google Scholar]
  68. Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. 1992 Feb 15;52(4):775–781. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES